{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:00:19Z","timestamp":1793520019634,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004329","name":"Genzyme Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lysosomal Disease Network","award":["U54NS065789"],"award-info":[{"award-number":["U54NS065789"]}]},{"name":"NIH Rare Diseases Clinical Research Network","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}]},{"name":"Lysosomal Disease Network","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}]},{"name":"NIH Rare Diseases Clinical Research Network"},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ymgme.2017.09.008","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T06:16:55Z","timestamp":1505888215000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T &gt; G \u201clate-onset\u201d GAA variant"],"prefix":"10.1016","volume":"122","author":[{"given":"Mugdha V.","family":"Rairikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoheb B.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit K.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Berrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Coats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1937-9503","authenticated-orcid":false,"given":"Rachel","family":"Gandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4506-8415","authenticated-orcid":false,"given":"Rebecca","family":"Quinones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.09.008_bb0005","series-title":"Scriver's OMMBID the Online Metabolic & Molecular Bases of Inherited Disease","article-title":"Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2009"},{"issue":"2","key":"10.1016\/j.ymgme.2017.09.008_bb0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.ymgme.2017.09.008_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"Pt 3","key":"10.1016\/j.ymgme.2017.09.008_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"issue":"9\u201310","key":"10.1016\/j.ymgme.2017.09.008_bb0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul. Disord."},{"issue":"4","key":"10.1016\/j.ymgme.2017.09.008_bb0030","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2017.09.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2017.09.008_bb0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ymgmr.2015.03.010","article-title":"Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy","volume":"3","author":"Gruhn","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2017.09.008_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"issue":"3","key":"10.1016\/j.ymgme.2017.09.008_bb0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin. Perinatol."},{"issue":"6","key":"10.1016\/j.ymgme.2017.09.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.ymgme.2017.09.008_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology, and early findings from the Pompe registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2017.09.008_bb0070","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with pompe disease: data from the pompe registry","volume":"161","author":"Kishnani","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"issue":"Supplement 1","key":"10.1016\/j.ymgme.2017.09.008_bb0075","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with pompe disease across the disease spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ymgme.2017.09.008_bb0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood Pompe disease: clinical spectrum and genotype in 31 patients","volume":"11","author":"van Capelle","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"8\u20139","key":"10.1016\/j.ymgme.2017.09.008_bb0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neurol.2013.07.002","article-title":"The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease","volume":"169","author":"Laforet","year":"2013","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.ymgme.2017.09.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.55.8.1122","article-title":"Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation","volume":"55","author":"Laforet","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2017.09.008_bb0105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.nmd.2015.07.002","article-title":"Homozygosity for the common GAA gene splice site mutation c.-32-13T&gt;G in Pompe disease is associated with the classical adult phenotypical spectrum","volume":"25","author":"Musumeci","year":"2015","journal-title":"Neuromuscul. Disord."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2017.09.008_bb0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jns.2015.08.007","article-title":"Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease","volume":"358","author":"Rafael Bret\u00f3n Mart\u00ednez","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nmd.2006.09.004","article-title":"Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations","volume":"17","author":"Palmer","year":"2007","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.gene.2015.02.023","article-title":"Novel GAA mutations in patients with Pompe disease","volume":"561","author":"Tura\u00e7a","year":"2015","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.ymgme.2017.09.008_bb0125","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","article-title":"Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment","volume":"262","author":"Montagnese","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2017.09.008_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood Pompe disease: clinical spectrum and genotype in 31 patients","volume":"11","author":"van Capelle","year":"2016","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.ymgme.2017.09.008_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/8904_2014_366","article-title":"Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset pompe disease identified by newborn screening","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Reports"},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.a.36197","article-title":"A large-scale nationwide newborn screening program for pompe disease in Taiwan: towards effective diagnosis and treatment","volume":"164","author":"Yang","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2017.09.008_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.pediatrneurol.2011.12.010","article-title":"Early pathologic changes and responses to treatment in patients with later-onset Pompe disease","volume":"46","author":"Chien","year":"2012","journal-title":"Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.ymgme.2017.09.008_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2010.11.053","article-title":"Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening","volume":"158","author":"Chien","year":"2011","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.ymgme.2017.09.008_bb0155","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00431-013-2258-2","article-title":"Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study","volume":"173","author":"Deroma","year":"2014","journal-title":"Eur. J. Pediatr."},{"issue":"6","key":"10.1016\/j.ymgme.2017.09.008_bb0160","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.09.008_bb0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"JV","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2017.09.008_bb0170","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/humu.20745","article-title":"Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating","volume":"29","author":"Kroos","year":"2008","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med. Genet."},{"issue":"10","key":"10.1016\/j.ymgme.2017.09.008_bb0180","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/humu.20374","article-title":"Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II","volume":"27","author":"Montalvo","year":"2006","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.31317","article-title":"Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgotten","volume":"160C","author":"Raben","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.09.008_bb0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2051-5960-2-2","article-title":"The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients","volume":"2","author":"Feeney","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"5","key":"10.1016\/j.ymgme.2017.09.008_bb0195","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2990.2007.00839.x","article-title":"Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited","volume":"33","author":"Schoser","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2009","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience","volume":"160C","author":"Bali","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2017.09.008_bb0210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease","volume":"11","author":"Lim","year":"2015","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.ymgme.2017.09.008_bb0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajmg.c.31321","article-title":"Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations","volume":"160C","author":"Case","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2017.09.008_bb0220","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ptj\/80.2.168","article-title":"Alberta infant motor scale: Reliability and validity when used on preterm infants in Taiwan","volume":"80","author":"Suh-Fang","year":"2000","journal-title":"Phys. Ther."},{"issue":"7","key":"10.1016\/j.ymgme.2017.09.008_bb0225","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1469-8749.1998.tb15399.x","article-title":"Assessment of gross motor skills of at-risk infants: predictive validity of the Alberta Infant Motor Scale","volume":"40","author":"Darrah","year":"1998","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2017.09.008_bb0230","series-title":"Motor Skills Acquisition in the First Year - An Illustrated Guide to Normal Development","author":"Bly","year":"1994"},{"issue":"5","key":"10.1016\/j.ymgme.2017.09.008_bb0235","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/01.gim.0000217789.14470.c5","article-title":"Physical therapy management of Pompe disease","volume":"8","author":"Case","year":"2006","journal-title":"Genet. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217305012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217305012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T02:40:55Z","timestamp":1719456055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217305012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1096719217305012"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.09.008","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}